All In Biotech

Drug Trial Radar · NCT07876284

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis

A Randomised, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeated Doses of Inhaled CHF10073 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Last checked: Nov 20, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Aug 2027

Study completion Aug 2027

Sponsor

Lead sponsor
Chiesi Farmaceutici S.p.A.Industry
Sponsor type
Industry
First posted
Oct 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to assess the safety and tolerability of repeated doses of CHF10073 and to characterise cough-related safety outcomes associated with CHF10073 administration. In addition, the study will also characterise the PK (pharmacokinetics) profile in plasma after repeated administrations of study drug.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • CHF10073 low doseDrug

    Multiple doses of CHF10073

  • CHF10073 high doseDrug

    Multiple doses of CHF10073

  • PlaceboDrug

    Multiple doses of placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number and % of participants with treatment-emergent adverse events, adverse drug reactions, serious and non-serious events, related and non-related events, severe events, events leading to discontinuation and events leading to deathTime frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose
  2. Change from baseline in systolic and diastolic blood pressureTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  3. Change from baseline in pulse rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  4. Change from baseline in respiratory rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  5. Change from baseline in body temperatureTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  6. Change from baseline in oxygen saturationTime frame: Day 1, Day 14 and Day 28 at pre-dose and 3 hours post-dose
  7. Number and percentage of participants with a change from baseline greater than 20 mmHg in systolic blood pressure and greater than 10 mmHg in diastolic blood pressure.Time frame: Day 1 through Follow-up visit, 35 to 42 days after the last dose
  8. Change from baseline in ECG heart rateTime frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  9. Change from baseline in ECG intervals: PR interval and QT interval corrected using Fridericia's formula.Time frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  10. Change from baseline in ECG: QRS durationTime frame: Day 1, Day 14 and Day 28 at pre-dose and at 3 hours post-dose (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  11. Number and percentage of participants with an increase from baseline in QT interval corrected using Fridericia's formula greater than 30 milliseconds and greater than 60 milliseconds.Time frame: Day 1 through Day 28 (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  12. Number and percentage of male participants with post-dose QT interval corrected using Fridericia's formula greater than 450, 480, and 500 milliseconds and female participants with values greater than 470 and 500 millisecondsTime frame: Day 1 through Day 28 (up to Follow-up visit, 35 to 42 days after the last dose for UK)
  13. Change and shift from baseline in clinical chemistry, including fasting glucose, and hematology evaluationsTime frame: Day 1, Day 14 and Day 28 at pre-dose
  14. Change from baseline in forced vital capacity and forced expiratory volume in 1 second.Time frame: Day 1 , Day 14 and Day 28 at pre-dose and 30 minutes post-dose

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.